OS Therapies Incorporated Common Stock (NY:OSTX)

1.710 +0.090 (+5.56%)

Official Closing Price Updated: 8:00 PM EST, Nov 21, 2025 Add to My Watchlist

Price and Volume

Volume	144,217
Open	1.640
Bid (Size)	1.610 (1,300)
Ask (Size)	1.700 (400)
Prev. Close	1.620
Today's Range	1.610 - 1.710
52wk Range	1.120 - 7.000
Shares Outstanding	5,847,955
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25

November 21, 2025

Dallas, Texas--(Newsfile Corp. - November 21, 2025) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage...

Via Newsfile

OS Therapies to Spinoff OS Animal Health into Standalone Public Company

November 20, 2025

Successful preliminary discussion with NYSE representatives and potential investorsOS Therapies shareholders to receive direct equity participation in new listing'Shelter Me:...

Via Newsfile

Performance

YTD	-59.1%	-59.1%
1 Month	-6.6%	-6.6%
3 Month	-31.0%	-31.0%
6 Month	+1.8%	+1.8%
1 Year	-7.9%	-7.9%

More News

OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

November 17, 2025

Via Newsfile

Earnings Outlook For OS Therapies ↗

August 18, 2025

Via Benzinga

Why Quantum Computing Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗

November 17, 2025

Via Benzinga

OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

October 22, 2025

Via Newsfile

OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

October 17, 2025

Via Newsfile

OS Therapies Reports Strong 2-Year Survival Data For Bone Cancer Immunotherapy Candidate ↗

October 10, 2025

Via Benzinga

OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

October 10, 2025

Via Newsfile

OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting

October 09, 2025

Via Newsfile

OS Therapies to Participate in Fall 2025 Conferences and Events

October 07, 2025

Via Newsfile

OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update

September 30, 2025

Via Newsfile

OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT

September 19, 2025

Via Newsfile

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

September 12, 2025

Via Newsfile

Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)

September 08, 2025

Via Newsfile

OS Therapies to Participate in Upcoming Investor Conferences in September 2025

September 03, 2025

Via Newsfile

OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting

September 02, 2025

Via Newsfile

OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing

September 02, 2025

Via Newsfile

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

August 27, 2025

Via Newsfile

OS Therapies Terminates Equity Line of Credit

August 25, 2025

Via Newsfile

Os Therapies Posts Wider Loss in Q2 ↗

August 19, 2025

Via The Motley Fool

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

August 19, 2025

Via Newsfile

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

August 14, 2025

Via Newsfile

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

August 07, 2025

Via Newsfile

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

August 07, 2025

Via Newsfile

Frequently Asked Questions

Is OS Therapies Incorporated Common Stock publicly traded?

Yes, OS Therapies Incorporated Common Stock is publicly traded.

What exchange does OS Therapies Incorporated Common Stock trade on?

OS Therapies Incorporated Common Stock trades on the New York Stock Exchange

What is the ticker symbol for OS Therapies Incorporated Common Stock?

The ticker symbol for OS Therapies Incorporated Common Stock is OSTX on the New York Stock Exchange

What is the current price of OS Therapies Incorporated Common Stock?

The current price of OS Therapies Incorporated Common Stock is 1.710

When was OS Therapies Incorporated Common Stock last traded?

The last trade of OS Therapies Incorporated Common Stock was at 11/21/25 08:00 PM ET

What is the market capitalization of OS Therapies Incorporated Common Stock?

The market capitalization of OS Therapies Incorporated Common Stock is 10.00M

How many shares of OS Therapies Incorporated Common Stock are outstanding?

OS Therapies Incorporated Common Stock has 10M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.